Maraş Baydoğan Gülseren, Ceyhan Özlem, Sağıroğlu Pınar, Ermiş Mustafa
Institute of Health Sciences, Surgical Nursing, Erciyes University, Kayseri, Türkiye.
Faculty of Health Sciences / Internal Medicine Nursing, Erciyes University, Kayseri, Türkiye.
World J Microbiol Biotechnol. 2025 Jun 25;41(7):231. doi: 10.1007/s11274-025-04453-0.
Bdellovibrio bacteriovorus is an agent that stands out with its predatory properties and has recently been used against pathogens that are frequently resistant to antibiotics. The study was conducted experimentally to determine the effect of dressing application containing Bdellovibrio bacteriovorus on superficial incisional surgical site infection caused by Staphylococcus aureus in mice. In the study, mice were divided into 6 different groups, BB: B. bacteriovorus; NC: Negative Control; PC: Positive Control Methicillin Resistant S. aureus; MRSA + BB: Methicillin Resistant S. aureus + B. bacteriovorus dressing; MRSA + V: Methicillin Resistant S. aureus + Vancomycin; MRSA + BB + V: Methicillin Resistant S. aureus + B. bacteriovorus dressing + Vancomycin group. The treatment procedures were applied over a period of 3 days. Infection symptoms were monitored and recorded at the 24th, 48th, and 72nd hours. In the Staphylococcus aureus + Vancomycin group, all mice developed edema, redness, and fever at 24 h. At 48 h, all mice exhibited edema and redness, with 50% showing fever. At 72 h, 70% of the mice showed edema and redness, and 10% showed fever. In the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin combined treatment group, all mice exhibited edema, redness, and fever at 24 h. At 48 h, only 20% of the mice showed redness. At 72 h, no edema, redness, fever, purulent discharge, or suture dehiscence was observed. Sepsis developed in 2 of 10 mice in the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin group. The most effective treatment was in the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin group. It was determined that sepsis findings were the least in the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin group. B. bacteriovorus holds the potential to be an effective control agent in preventing or slowing resistance development.
食菌蛭弧菌是一种以其捕食特性而脱颖而出的病原体,最近被用于对抗那些经常对抗生素耐药的病原体。该研究通过实验来确定含有食菌蛭弧菌的敷料对小鼠金黄色葡萄球菌引起的浅表切口手术部位感染的影响。在该研究中,小鼠被分为6个不同的组,BB:食菌蛭弧菌;NC:阴性对照;PC:耐甲氧西林金黄色葡萄球菌阳性对照;MRSA + BB:耐甲氧西林金黄色葡萄球菌 + 食菌蛭弧菌敷料;MRSA + V:耐甲氧西林金黄色葡萄球菌 + 万古霉素;MRSA + BB + V:耐甲氧西林金黄色葡萄球菌 + 食菌蛭弧菌敷料 + 万古霉素组。治疗程序持续3天。在第24、48和72小时监测并记录感染症状。在金黄色葡萄球菌 + 万古霉素组中,所有小鼠在24小时时均出现水肿、发红和发热。在48小时时,所有小鼠均出现水肿和发红,50%出现发热。在72小时时,70%的小鼠出现水肿和发红,10%出现发热。在金黄色葡萄球菌 + 食菌蛭弧菌 + 万古霉素联合治疗组中,所有小鼠在24小时时均出现水肿、发红和发热。在48小时时,仅20%的小鼠出现发红。在72小时时,未观察到水肿、发红、发热、脓性分泌物或缝线裂开。在金黄色葡萄球菌 + 食菌蛭弧菌 + 万古霉素组的10只小鼠中有2只发生败血症。最有效的治疗方法是在金黄色葡萄球菌 + 食菌蛭弧菌 + 万古霉素组。确定在金黄色葡萄球菌 + 食菌蛭弧菌 + 万古霉素组中败血症的发生率最低。食菌蛭弧菌有潜力成为预防或减缓耐药性发展的有效控制剂。